TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis
Brief Summary: The study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) BID for 4 weeks.


Options:
A: Arm Label: Treatment group A; Type: EXPERIMENTAL; Interventions: Drug: Tofacitinib ointment 20mg/g | Arm Label: Treatment B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo ointment (Vehicle) | Intervention Type: DRUG; Name: Tofacitinib ointment 20mg/g; Assigned to Arm(s): Treatment group A | Intervention Type: DRUG; Name: Placebo ointment (Vehicle); Assigned to Arm(s): Treatment B
B: Arm Label: AN2728 Topical Ointment, 2%; Type: EXPERIMENTAL; Interventions: Drug: AN2728 Topical Ointment, 2% | Arm Label: Matching vehicle control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching vehicle control | Intervention Type: DRUG; Name: AN2728 Topical Ointment, 2%; Assigned to Arm(s): AN2728 Topical Ointment, 2% | Intervention Type: DRUG; Name: Matching vehicle control; Assigned to Arm(s): Matching vehicle control
C: Arm Label: Betamethasone-17-valerat + placebo ointment; Type: EXPERIMENTAL; Interventions: Drug: Betnovate, betamethasone dipropionate ointment 0.1% and placebo | Arm Label: Tacrolimus ointment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Protopic, tacrolimus ointment 0.1% | Intervention Type: DRUG; Name: Betnovate, betamethasone dipropionate ointment 0.1% and placebo; Assigned to Arm(s): Betamethasone-17-valerat + placebo ointment | Intervention Type: DRUG; Name: Protopic, tacrolimus ointment 0.1%; Assigned to Arm(s): Tacrolimus ointment
D: Arm Label: Arm 1 - Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: EUCRISA | Arm Label: Arm 2 - Online Treatment Response; Type: EXPERIMENTAL; Interventions: Behavioral: Online Treatment response, Drug: EUCRISA | Intervention Type: BEHAVIORAL; Name: Online Treatment response; Assigned to Arm(s): Arm 2 - Online Treatment Response | Intervention Type: DRUG; Name: EUCRISA; Assigned to Arm(s): Arm 1 - Standard of Care, Arm 2 - Online Treatment Response

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis
Brief Summary: The study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) BID for 4 weeks.


Options:
A: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 300 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 100 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo qw
B: Arm Label: 20 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): 20 mg BID, 30 mg BID
C: Arm Label: Treatment group A; Type: EXPERIMENTAL; Interventions: Drug: Tofacitinib ointment 20mg/g | Arm Label: Treatment B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo ointment (Vehicle) | Intervention Type: DRUG; Name: Tofacitinib ointment 20mg/g; Assigned to Arm(s): Treatment group A | Intervention Type: DRUG; Name: Placebo ointment (Vehicle); Assigned to Arm(s): Treatment B
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Dupilumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms
Brief Summary: This three-site randomized controlled trial compares the effectiveness and cost-effectiveness of a group-administered behavioral treatment program to no treatment. Women with stress, urgency, or mixed urinary incontinence will be recruited and screened centrally, evaluated clinically at each of three study sites, and random assigned to one of two treatment arms: 1. Group behavioral treatment or 2. No treatment. Group treatment modalities have the potential to reach a larger population of older women with urinary incontinence, not only in the traditional medical settings, but also in community settings. The investigators hypothesize that group behavioral treatment will be more effective than no treatment. The investigators hypothesize that the group treatment will be cost-effective compared to no treatment.


Options:
A: Arm Label: Tät®II Treatment app; Type: EXPERIMENTAL; Interventions: Device: Tät®II Treatment app | Arm Label: Tät®II Information app; Type: OTHER; Interventions: Device: Tät®II Information app | Intervention Type: DEVICE; Name: Tät®II Information app; Assigned to Arm(s): Tät®II Information app | Intervention Type: DEVICE; Name: Tät®II Treatment app; Assigned to Arm(s): Tät®II Treatment app
B: Arm Label: Group Behavioral Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Group Behavioral Treatment | Arm Label: No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group Behavioral Treatment; Assigned to Arm(s): Group Behavioral Treatment
C: Arm Label: Group Bladder Training; Type: EXPERIMENTAL; Interventions: Other: Bladder Training | Arm Label: Group TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: TMAP | Arm Label: Group Bladder Training + TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: Bladder Training + TMAP | Intervention Type: OTHER; Name: Bladder Training; Assigned to Arm(s): Group Bladder Training | Intervention Type: OTHER; Name: TMAP; Assigned to Arm(s): Group TMAP | Intervention Type: OTHER; Name: Bladder Training + TMAP; Assigned to Arm(s): Group Bladder Training + TMAP
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Simplified bladder training | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Simplified bladder training; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms
Brief Summary: This three-site randomized controlled trial compares the effectiveness and cost-effectiveness of a group-administered behavioral treatment program to no treatment. Women with stress, urgency, or mixed urinary incontinence will be recruited and screened centrally, evaluated clinically at each of three study sites, and random assigned to one of two treatment arms: 1. Group behavioral treatment or 2. No treatment. Group treatment modalities have the potential to reach a larger population of older women with urinary incontinence, not only in the traditional medical settings, but also in community settings. The investigators hypothesize that group behavioral treatment will be more effective than no treatment. The investigators hypothesize that the group treatment will be cost-effective compared to no treatment.


Options:
A: Arm Label: Group Behavioral Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Group Behavioral Treatment | Arm Label: No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Group Behavioral Treatment; Assigned to Arm(s): Group Behavioral Treatment
B: Arm Label: 1 Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: 2 Bladder Health Class; Type: EXPERIMENTAL; Interventions: Behavioral: Bladder Health class | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): 1 Usual Care | Intervention Type: BEHAVIORAL; Name: Bladder Health class; Assigned to Arm(s): 2 Bladder Health Class
C: Arm Label: Exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Arm Label: non-exercice; Type: OTHER; Interventions: Behavioral: preparation of the delivery | Intervention Type: BEHAVIORAL; Name: preparation of the delivery; Assigned to Arm(s): Exercice, non-exercice
D: Arm Label: Electroacupuncture group; Type: EXPERIMENTAL; Interventions: Device: Electroacupuncture | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Device: Sham Electroacupuncture | Arm Label: Solifenacin Succinate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin Succinate | Intervention Type: DEVICE; Name: Electroacupuncture; Assigned to Arm(s): Electroacupuncture group | Intervention Type: DEVICE; Name: Sham Electroacupuncture; Assigned to Arm(s): Placebo group | Intervention Type: DRUG; Name: Solifenacin Succinate; Assigned to Arm(s): Solifenacin Succinate group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Fluid Translation of Research Into Practice Study (Fluid-TRIPS): An International Cross-Sectional Survey of Fluid Resuscitation Practice
Brief Summary: Translating reliable evidence on fluid resuscitation of intensive care patients into clinical practice - Improving patient outcomes and containing public health costs


Options:
A: Arm Label: multiple electrolyte solution; Type: EXPERIMENTAL; Interventions: Drug: multiple electrolyte solution | Arm Label: saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: saline | Intervention Type: DRUG; Name: multiple electrolyte solution; Assigned to Arm(s): multiple electrolyte solution | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): saline
B: Arm Label: Plasma-Lyte, Slow Infusion; Type: EXPERIMENTAL; Interventions: Drug: Plasma-Lyte, Other: Slow infusion speed | Arm Label: Plasma-Lyte, Fast Infusion; Type: EXPERIMENTAL; Interventions: Drug: Plasma-Lyte, Other: Fast Infusion Speed | Arm Label: Saline 0.9%, Slow Infusion; Type: EXPERIMENTAL; Interventions: Drug: Saline 0.9%, Other: Slow infusion speed | Arm Label: Saline 0.9%, Fast Infusion; Type: EXPERIMENTAL; Interventions: Drug: Saline 0.9%, Other: Fast Infusion Speed | Intervention Type: DRUG; Name: Plasma-Lyte; Assigned to Arm(s): Plasma-Lyte, Fast Infusion, Plasma-Lyte, Slow Infusion | Intervention Type: DRUG; Name: Saline 0.9%; Assigned to Arm(s): Saline 0.9%, Fast Infusion, Saline 0.9%, Slow Infusion | Intervention Type: OTHER; Name: Slow infusion speed; Assigned to Arm(s): Plasma-Lyte, Slow Infusion, Saline 0.9%, Slow Infusion | Intervention Type: OTHER; Name: Fast Infusion Speed; Assigned to Arm(s): Plasma-Lyte, Fast Infusion, Saline 0.9%, Fast Infusion
C: Arm Label: Adult ICU patient receiving Fluid resus; Type: N/A; Interventions: N/A
D: Arm Label: Lactated ringers solution; Type: EXPERIMENTAL; Interventions: Drug: Lactated Ringer Solution | Arm Label: Normal saline solution; Type: EXPERIMENTAL; Interventions: Drug: Normal Saline 0.9% Infusion Solution Bag | Intervention Type: DRUG; Name: Lactated Ringer Solution; Assigned to Arm(s): Lactated ringers solution | Intervention Type: DRUG; Name: Normal Saline 0.9% Infusion Solution Bag; Assigned to Arm(s): Normal saline solution

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)
Brief Summary: The purpose of this study is to clarify efficacy and safety of MRI-based intravenous thrombolysis with alteplase for patients with acute wake-up ischemic stroke and those having acute ischemic stroke with unknown time of symptom onset.


Options:
A: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Alteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alteplase; Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intra-arterial Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Intra-arterial Therapy | Intervention Type: PROCEDURE; Name: Intra-arterial Therapy; Assigned to Arm(s): Intra-arterial Therapy
C: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
D: Arm Label: Alteplase; Type: EXPERIMENTAL; Interventions: Drug: Tissue-type plasminogen activator (alteplase) | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard care | Intervention Type: DRUG; Name: Tissue-type plasminogen activator (alteplase); Assigned to Arm(s): Alteplase | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transcutaneous Auricular Vagus Nerve Stimulation as a Complementary Treatment for Pediatric Epilepsy
Brief Summary: The purpose of this study is to determine whether transcutaneous auricular vagus nerve stimulation as a complementary therapy is effective in the treatment of pediatric epilepsy.


Options:
A: Arm Label: Model 106 VNS Therapy System; Type: OTHER; Interventions: Device: M106 VNS Therapy System | Intervention Type: DEVICE; Name: M106 VNS Therapy System; Assigned to Arm(s): Model 106 VNS Therapy System
B: Arm Label: Model 106 VNS Therapy System; Type: OTHER; Interventions: Device: Model 106 VNS Therapy System | Intervention Type: DEVICE; Name: Model 106 VNS Therapy System; Assigned to Arm(s): Model 106 VNS Therapy System
C: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Device: PINS Vagus Nerve Stimualtor | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Device: PINS Vagus Nerve Stimualtor | Intervention Type: DEVICE; Name: PINS Vagus Nerve Stimualtor; Assigned to Arm(s): Control, Experimental
D: Arm Label: Transcutaneous auricular vagal stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: ear vagus nerve stimulator | Arm Label: Transcutaneous auricular non-vagal stimulation; Type: SHAM_COMPARATOR; Interventions: Device: ear vagus nerve stimulator | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ear vagus nerve stimulator; Assigned to Arm(s): Transcutaneous auricular non-vagal stimulation, Transcutaneous auricular vagal stimulation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery
Brief Summary: Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery


Options:
A: Arm Label: IV acetaminophen & IV propofol; Type: EXPERIMENTAL; Interventions: Drug: IV acetaminophen & IV propofol | Arm Label: IV acetaminophen & IV dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: IV acetaminophen & IV dexmedetomidine | Arm Label: IV propofol & placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV propofol & placebo | Arm Label: IV dexmedetomidine & placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV dexmedetomidine & placebo | Intervention Type: DRUG; Name: IV acetaminophen & IV propofol; Assigned to Arm(s): IV acetaminophen & IV propofol | Intervention Type: DRUG; Name: IV acetaminophen & IV dexmedetomidine; Assigned to Arm(s): IV acetaminophen & IV dexmedetomidine | Intervention Type: DRUG; Name: IV propofol & placebo; Assigned to Arm(s): IV propofol & placebo | Intervention Type: DRUG; Name: IV dexmedetomidine & placebo; Assigned to Arm(s): IV dexmedetomidine & placebo
B: Arm Label: Dexmedetomidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: N/A
D: Arm Label: Rhythm control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiodarone, Procedure: DC-cardioversion | Arm Label: Rate control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rate Control | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): Rhythm control | Intervention Type: PROCEDURE; Name: DC-cardioversion; Assigned to Arm(s): Rhythm control | Intervention Type: DRUG; Name: Rate Control; Assigned to Arm(s): Rate control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Monitoring and Evaluation of an MNCH Mentoring Intervention in Two Districts of Karnataka
Brief Summary: Our hypothesis is that an on-site mentoring program for staff at primary health care centers in northern Karnataka, will improve the quality of maternal, neonatal and child health care, and improve clinical outcomes.


Options:
A: Arm Label: Full - Train/oxy&miso/ B&M/Mentor/Phone; Type: EXPERIMENTAL; Interventions: Other: Helping Mothers Survive - Bleeding After Birth training, Other: Helping Babies Breathe, Behavioral: Mentor, Behavioral: Phone, Drug: oxytocin and misoprostol, Device: Newborn bag and mask | Arm Label: Partial - Train/oxy & miso/ B&M/Mentor; Type: EXPERIMENTAL; Interventions: Other: Helping Mothers Survive - Bleeding After Birth training, Other: Helping Babies Breathe, Behavioral: Mentor, Drug: oxytocin and misoprostol, Device: Newborn bag and mask | Arm Label: Comparison - Train/oxy & miso/ B&M; Type: ACTIVE_COMPARATOR; Interventions: Other: Helping Mothers Survive - Bleeding After Birth training, Other: Helping Babies Breathe, Drug: oxytocin and misoprostol, Device: Newborn bag and mask | Intervention Type: OTHER; Name: Helping Mothers Survive - Bleeding After Birth training; Assigned to Arm(s): Comparison - Train/oxy & miso/ B&M, Full - Train/oxy&miso/ B&M/Mentor/Phone, Partial - Train/oxy & miso/ B&M/Mentor | Intervention Type: OTHER; Name: Helping Babies Breathe; Assigned to Arm(s): Comparison - Train/oxy & miso/ B&M, Full - Train/oxy&miso/ B&M/Mentor/Phone, Partial - Train/oxy & miso/ B&M/Mentor | Intervention Type: BEHAVIORAL; Name: Mentor; Assigned to Arm(s): Full - Train/oxy&miso/ B&M/Mentor/Phone, Partial - Train/oxy & miso/ B&M/Mentor | Intervention Type: BEHAVIORAL; Name: Phone; Assigned to Arm(s): Full - Train/oxy&miso/ B&M/Mentor/Phone | Intervention Type: DRUG; Name: oxytocin and misoprostol; Assigned to Arm(s): Comparison - Train/oxy & miso/ B&M, Full - Train/oxy&miso/ B&M/Mentor/Phone, Partial - Train/oxy & miso/ B&M/Mentor | Intervention Type: DEVICE; Name: Newborn bag and mask; Assigned to Arm(s): Comparison - Train/oxy & miso/ B&M, Full - Train/oxy&miso/ B&M/Mentor/Phone, Partial - Train/oxy & miso/ B&M/Mentor
B: Arm Label: Mentoring intervention; Type: EXPERIMENTAL; Interventions: Other: Mentoring intervention | Arm Label: No mentoring intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mentoring intervention; Assigned to Arm(s): Mentoring intervention
C: Intervention Type: BEHAVIORAL; Name: Opinion Leaders, Academic Detailing, Reminders, and Feedback; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: ESCALATES; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving High School Breakfast Environments
Brief Summary: The goals of this intervention study are to implement best practice strategies to expand and promote the school breakfast program and test the impact upon student participation rates among a) all 10th and 11th grade students and among a randomly selected cohort of 800 students b) total diet and body mass index and percent body fat inin 16 rural Minnesota school districts.

School-wide Primary Aim: Improve participation in the school breakfast program among high school students. Hypothesis: School-wide school breakfast program participation will be higher in the intervention versus comparison group.


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-face family mentoring and education sessions, Behavioral: Telephone follow-up | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Face-to-face family mentoring and education sessions; Assigned to Arm(s): Intervention Group | Intervention Type: BEHAVIORAL; Name: Telephone follow-up; Assigned to Arm(s): Intervention Group
B: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Improve access to the school breakfast program | Arm Label: Comparison arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Improve access to the school breakfast program; Assigned to Arm(s): Intervention arm
C: Arm Label: New Moves Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: New Moves | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: New Moves; Assigned to Arm(s): New Moves Intervention Group
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Students for Nutrition and eXercise; Type: EXPERIMENTAL; Interventions: Behavioral: Students for Nutrition and eXercise | Intervention Type: BEHAVIORAL; Name: Students for Nutrition and eXercise; Assigned to Arm(s): Students for Nutrition and eXercise

Answer: B